



Supplementary Figure 1




Supplementary Figure 1. IL17A epitope-specific antibody titer through 9 weeks. Antibody titers for IL17A epitope were measured by ELISA. Serum dilution from 10x to x31250. (A) 0w (Pre-vaccination), (B) 2w, (C) 4w, (D) 6w, (E) 9w, See also Figure 1.

Supplementary Figure 2




Supplementary Figure 2. IL17A vaccine suppresses enthesitis and bone remodeling in the joints of HLA-B27 transgenic rats. X-ray image of joint of the spine and ankle. Arrows indicate bone destruction. See also Figure 3.

Supplementary Figure 3



Supplementary Figure 3. IL17A vaccine suppresses enthesitis and bone remodeling in the joint of HLA-B27 transgenic rats. Representative whole images of spine and ankle with (A) HE and CD68 staining, and (B) CD14 and ALP staining. Enlarged image of black square (enthesitis) is shown in Figure 3. See also Figure 3.

Supplementary Figure 4

**Supplementary Figure 4. IL17A epitope-specific antibody titer through 10 weeks in therapeutic model.**

Antibody titers for IL17A epitope were measured by ELISA. Serum dilution from 10x to x31250.

(A) 1w (Pre-vaccination), (B) 3w, (C) 5w, (D) 7w, (E) 10w, See also Figure 5.